Host defense, chemical immunosuppression, and the transplant recipient. Relative effects of intermittent versus continuous immunosuppressive therapy with reference to the objectives of treatment.
D000917:Antibody Formation; D000942:Antigens, Bacterial; D000946:Antigens, Fungal; D003883:Arthrodermataceae / Q000276:immunology; D002175:Candida / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004338:Drug Combinations; D006433:Hemocyanins; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007109:Immunity; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007938:Leukemia / Q000188:drug therapy*; D008213:Lymphocyte Activation; D009107:Mumps / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012882:Skin Tests; D013299:Streptodornase and Streptokinase; D014181:Transplantation Immunology; D014750:Vincristine / Q000627:therapeutic use
D000942:Antigens, Bacterial; D000946:Antigens, Fungal; D004338:Drug Combinations; D007166:Immunosuppressive Agents; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D006433:Hemocyanins; D013299:Streptodornase and Streptokinase; D011241:Prednisone